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The measurement of hemoglobin A 1c (Hb A 1c ) 2 is integral to the management of patients with diabetes. Hb A 1c is used in the evaluation of long-term (8 -12 weeks) glucose control, to alter therapy and predict the risk for development of microvascular complications, and as a criterion to diagnose diabetes. Early Hb A 1c assays measured different forms of glycohemoglobin and lacked standardization. The publication of the Diabetes Control and Complications Trial (DCCT) in 1993 motivated the development of standardization programs in Japan, Sweden, and the US. The National Glycohemoglobin Standardization Program (official name later shortened to the acronym NGSP) was by far the most widely implemented program around the world, being used in the vast majority of countries that had Hb A 1c standardization. The subsequent development of a reference measurement system by the IFCC led to several meetings to effect universal standardization of Hb A 1c . 
